^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    OTOA (Otoancorin)

    i
    Other names: OTOA, Otoancorin, CT108, Cancer/Testis Antigen 108, DFNB22, Deafness, Autosomal Recessive 22
    Associations

    News

    Trials
    1year
    Copy-number analysis from genome sequencing data of 11,754 rare-disease parent-child trios: A model for identifying autosomal recessive human gene knockouts including a novel gene for autosomal recessive retinopathy. (PubMed, Genet Med Open)
    A tailored copy-number variations analysis of genome sequencing trio data shows that biallelic inherited gene deletions are rare, with NPHP1 biallelic deletions causing nephronophthisis the leading finding. We propose SLC66A1 as a novel cause for AR retinopathy.
    Journal
    |
    OTOA (Otoancorin)
    almost4years
    Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer. (PubMed, BMC Cancer)
    This study predicted the efficacy of nivolumab based on a comprehensive analysis of mRNA expression at the gene level in advanced NSCLC. We also revealed different gene expression patterns as predictors of the effectiveness of anti PD-1 antibody therapy in adenocarcinoma and squamous cell carcinoma.
    Retrospective data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    MAGEA4 (Melanoma antigen family A, 4) • CDH2 (Cadherin 2) • BBC3 (BCL2 Binding Component 3) • OTOA (Otoancorin)
    |
    Opdivo (nivolumab)